FDA puts clinical hold on Solid Biosciences’ gene therapy trial for Duchenne muscular dystrophy over toxicity concerns – Genetic Literacy Project
Genetic Literacy Project |
FDA puts clinical hold on Solid Biosciences' gene therapy trial for Duchenne muscular dystrophy over toxicity concerns
Genetic Literacy Project The FDA has imposed a full clinical hold on Solid Biosciences' Phase I/II trial for its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, the company acknowledged. GNITE DMD had been on a partial clinical hold since November … Financial Contrast: Solid Biosciences (SLDB) & Its Peers |
